Transforming Precision Medicine with Multimodal AI

BioAI is a biotechnology company employing world-leading AI technology to map the causal biology of disease, develop digital biomarkers and identify novel drug targets for the development of better medicine.

Our Mission

At BioAI, our mission is to develop AI-powered precision biomarkers and discover novel drug targets to accelerate clinical R&D and to revolutionize precision medicine.

Our Purpose

Our purpose is to develop novel AI solutions for precision medicine to improve patient care and quality of life.

Our Values


We are dedicated to excellence in innovation, driving the continuous advancement of AI technologies in precision medicine, and staying at the forefront of scientific and technological breakthroughs in Biopharma.

Patient Empowerment

We are on a journey to improve patient outcomes. At BioAI, we are committed to empowering patients with more personalized treatment options, conquering cancer one data point at a time.


Upholding the highest ethical standards is essential in our field where research and development directly impact patient care and also often involve sensitive information. From partner and patient confidentiality to ethical AI, we maintain integrity in all aspects of operations.


BioAI believes in the power of interdisciplinary collaboration and teamwork bringing together experts from multiple fields and fostering relationships with healthcare providers, research institutions and biopharmaceutical partners.


Meet the Team

Meet our leadership team, scientific advisory board, and growing board of industry experts and partners. Our multidisciplinary team has expertise across machine learning, medicine, and biology.

Leadership Team

Thomas Colarusso

Chief Executive Officer, Co-founder

Hon. Prof. Tom Chittenden, PhD, DPhil, PStat

Chief Scientific Officer, President of R&D

Alan Jerusalmi, PhD

Chief Innovation Officer, Co-founder

Thomas Colarusso

Chief Executive Officer, Co-founder

Alan Jerusalmi, PhD

Chief Innovation Officer, Co-founder

Martin Baatz, PhD

Chief Operating Officer

Mike Bonham MD,PhD

Chief Pathologist, Executive Medical Director

Scientific Advisory Board

Hon. Prof. Tom Chittenden, PhD, DPhil, PStat

SAB Chairman, CSO at BullFrog AI, Honorary Professor of AI in Biomedicine at Queen Mary University of London

Paolo Ascierto, MD

BioAI Advisory Board, Director of the Department of Melanoma Cancer Immunotherapy at Institute of National Tumor IRCCS Foundation

J. Carl Barrett, PhD

Chief Scientific Officer at Precede Biosciences

Daniel Lidar, PhD

BioAI Advisory Board, Viterbi Professor of Engineering at USC, Co-founder and Director of Center for Quantum Information Science & Technology, USC

Carlo Bifulco, MD

BioAI Advisory Board, Chief Medical Officer of Providence Genomics, Medical Director, Translational Pathology at Earle A. Chiles Research Institute

Greg Slabaugh, PhD

BioAI Advisory Board, Professor, and Director of the Digital Environment Research Institute (DERI) at Queen Mary University of London

Advisory Team

Michael Vergato

BioAI Advisory Board, Chief Data Architect, Co-founder

Jill Stefanelli, PhD

BioAI Advisory Board, Precision Medicine Consultant

Alex Lazar, MD, PhD

BioAI Advisory Board, Professor of Pathology, Genomic Medicine, Translational Molecular Pathology

Arno Schäpe

BioAI Advisory Board, CTO at Noselab

Markus Rinecker, MD, MBA

BioAI Advisory Board, Co-Founder and Managing Director at mbiomics GmbH

Kamala Maddali, DVM, PhD

President & Founder at Health Collaborations

Drew Watson, PhD, MBA

BioAI Advisory Board, Sr. VP Clinical Studies and Biostatistics at CellMax Life

Peter Blume-Jensen, MD, PhD

BioAI Advisory Board, President and CEO at Acrivon Therapeutics

Thomas Nifong, MD

VP, Head CDx Operations at Acrivon Therapeutics